From Our 2010 Archives
Zyclara Approved to Treat Pre-Cancerous Skin Condition
Latest Cancer News
FRIDAY, March 26 (HealthDay News) -- Zyclara topical cream (imiquimod 3.75%) has been approved by the U.S. Food and Drug Administration to treat actinic keratoses (AKs), a precancerous condition that's commonly found on skin frequently exposed to the sun.
AKs -- sometimes confused with eczema or psoriasis -- are small, red patches of skin that also may be scaly or rough, drug maker Graceway Pharmaceuticals said. They are most often found on the face, bald scalp, hands, shoulders and arms. Some 10 million Americans have the condition, which tends to recur, the company said in a news release.
AKs should be treated without delay, since they may progress to a form of skin cancer called squamous cell carcinoma. In clinical testing involving people with five to 20 AKs on the face or scalp, Zyclara reduced the total number of AKs by 82%, the news release said.
The most common side effects reported were local skin reactions with redness, scabbing or crusting, and sores or ulcers.
-- Scott Roberts
Copyright © 2010 HealthDay. All rights reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions